NVAX

Price & events

Pipeline stages · 3 programs

Pipeline · 3 trials · 0 upcoming

Catalyst news & presentations · 10

• 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
• first quarter of 2026regulatory submissionFiled (NDA/BLA)Nuvaxovid · Anticipated receipt of $25 million milestone payment from Sanofi.SEC 8-K
• January 12, 2026conferencedata presentationsecondaryCOVID-19 Vaccine · 44th Annual J.P. Morgan Healthcare Conference presentationSEC 8-K
• 2025-11-03partnershipNuvaxovid · FDA approved transfer of U.S. marketing authorization for Nuvaxovid from Novavax to Sanofi, triggering $25M milestone payment.SEC 8-K
• initial cohortreadoutPhase 3COVID-19-Influenza Combination (CIC) vaccine candidate; Stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) vaccine candidate · Initial cohort of Phase 3 trial for CIC and tNIV vaccine candidates topline results announced.SEC 8-K
• May 22, 2025AdCommAdCommNuvaxovid · FDA VRBPAC meeting to recommend 2025-2026 COVID-19 vaccine formula strain.SEC 8-K
• 2025-04-23fda agreementCOVID-19 Vaccine · FDA requested post marketing commitment to generate additional clinical data for BLA.SEC 8-K
• April 1, 2025PDUFAPDUFACOVID-19 Vaccine · PDUFA date for BLA seeking approval of COVID-19 vaccine; FDA has not yet issued decision.SEC 8-K
• 2024-11-11fda agreementCOVID-19-Influenza Combination vaccine, stand-alone influenza vaccine · FDA removed clinical hold on IND for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates.SEC 8-K
• 2024-10-16clinical holdCOVID-19-Influenza Combination vaccine, stand-alone influenza vaccine · FDA placed clinical hold on IND for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates.SEC 8-K